Navigation Links
New Type of Stent Appears Safe, Effective
Date:9/1/2008

Artery-opening device emits drug from a biodegradable polymer

MONDAY, Sept. 1 (HealthDay News) -- One of a "new generation" of artery-opening, drug-eluting stents appears equally effective as older models in boosting outcomes for heart patients, a new head-to-head study shows.

Stents are tiny mesh tubes inserted into arteries to keep blood flowing. Drug-eluting stents emit medicines that help prevent reclosure. The latest form of drug-eluting stents releases the drugs from a biodegradable polymer coating.

In the new study, published early online Sept. 1 in The Lancet, researchers in Switzerland compared one such stent, which releases the drug biolimus, against a standard drug-eluting stent releasing sirolimus. Adult heart patients with chronic stable coronary artery disease or acute coronary syndromes were randomized to receive either of the two stents. A subset (427 patients) later underwent angiography to see how well the stent was performing.

After nine months of follow-up, researchers led by Professor Stephan Windecker of Bern University Hospital reported that biolimus-eluting stents were as effective as the sirolimus stent in terms of the number of patients who experienced a combination of cardiac death, heart attack or need for a repeat revascularization procedure of the treated vessel -- 9 percent for the biolimus group and 11 percent for those receiving the sirolimus stent.

There were also no significant difference between the biolimus and sirolmus stent groups when each event was looked at separately: cardiac death (1.6 percent vs. 2.5 percent, respectively), heart attack (5.7 percent vs. 4.6 percent) and repeat procedures (4.4 percent vs. 5.5 percent). Each stent also performed similarly in terms of the percentage of vessel diameter that reclosed over the nine-month period, the team noted.

According to the authors, the study, "establishes the non-inferiority" of the newer biolimus-eluting stent.

But in an editorial, Dr. Ron Waksman, of Washington Hospital Center, Washington, D.C., was more cautious. "Before we become overly enthused with new-generation drug-eluting stents, we should call for new-generation trial designs that will enable us to assess whether or not these new stents are necessarily better," he wrote.

The study, which was expected to be presented Monday at the European Society of Cardiology meeting in Munich, was funded by the maker of the biolimus stent, Biosensors Europe SA, Switzerland.

More information

There's more on stents and stenting at the American Heart Association.



-- E.J. Mundell



SOURCE: The Lancet, news release, Sept. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. MD On-Line Achieves CAQH CORE(TM) Certification for Consistent Healthcare Administrative Data Exchange
2. NYC first: Complex aneurysm treated using new fenestrated endograft stent
3. Drug-Coated Stents Reduce Repeat Artery Procedures
4. How to use endoscopic stent for biliary stricture trauma?
5. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
8. More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
9. Study analyzed SYMBICORT in children with persistent asthma
10. High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
11. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern ... Epilepsy Foundation in a community wide charity event with the goal of bringing in ... young local woman who lives with epilepsy, recently launched a charity campaign of her ...
(Date:7/21/2017)... ... 2017 , ... The Karen Miller Agency, a central Alabama ... greater Birmingham area, is joining the Chris Hammond Youth Foundation in a charity ... , The Chris Hammond Youth Foundation maintains athletic facilities in rural areas that ...
(Date:7/21/2017)... Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... safely and effectively eliminate severe cannabis and tobacco smoke odors without the use of ...
(Date:7/21/2017)... ... ... Hospital M&A activity slowed in the second quarter of 2017, according to new ... in the second quarter, up 15% from the 20 publicly announced acquisitions in the ... year-ago second quarter. Only four of the transactions disclosed a purchase price in the ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
Breaking Medicine Technology: